Previous Frame Next Frame
  • Discover: How Intrexon
    is creating the code for a
    healthier planet

    World Demand
  • Intrexon Energy Partners to
    Generate High-value Oil Products
    from Low-Cost Natural Gas

    DISCOVER

    Intrexon Energy Partners to Generate High-value Oil Products from Low-Cost Natural Gas
  • Optimizing therapeutics production:
    Improving the way we generate active pharmaceutical ingredients

    DISCOVER

    Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Intrexon and Johnson & Johnson to
    advance new hair and skin products

    DISCOVER

    Johnson & Johnson Innovation
  • Next-generation fertility solutions

    DISCOVER

    OvaScience
  • World Demand
  • Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Johnson & Johnson Innovation
  • OvaScience

UltraVector® platform to power the next generation of bio-based products
LEAP® automated purification of high value cells
RheoSwitch® precisely controlled expression
IN THE SPOTLIGHT
HEALTH
Collaboration:
Ziopharm and Intrexon are on the path to treating melanoma
FOOD
Extreme Weather:
Drought and the need for novel food applications
ENERGY
Engineering Energy:
Fueling the world with microbes
LATEST NEWS
Intrexon Announces the Appointment of Peter Emtage, Ph.D., as Vice President, Synthetic Immunology
GERMANTOWN, Md., Dec. 4, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Peter Emtage, Ph.D., as Vice President, Synthetic Immunology.  Dr. Emtage will focus on further advancing the Company's oncology and immunology platforms to bring the next generation of cellular-based solutions that overcome the limitations of current treatments and address the most challenging malignancies.  "We are thrilled to have Peter join the executive team and look forward to his leadership within our expanding synthetic immunology group," said Krish S. Krishnan, Chief Operating Officer of Intrexon.  "Peter's expertise in guiding multi-f...
ZIOPHARM and Intrexon Present Clinical and Preclinical Data From Immuno-Oncology Programs at AACR Tumor Immunology and Immunotherapy Meeting
BOSTON, Mass. and GERMANTOWN, Md., Dec. 3, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced the presentation of clinical and preclinical studies from their immuno-oncology programs at the American Association for Cancer Research (AACR) 2014 Immunology and Immunotherapy Meeting taking place December 1-4, 2014 in Orlando, Florida. Presentations include: Clinical results from the Ad-RTS-hIL-12 + veledimex studies in patients with advanced breast cancer and melanoma demonstrating local and sys...
Intrexon Announces Third Quarter 2014 Financial Results
GERMANTOWN, Md., Nov. 13, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its third quarter results for 2014.  Business Highlights and Recent Developments: Closed the acquisition of Trans Ova Genetics, L.C. ("Trans Ova"), an industry-leading provider of bovine reproductive technologies and the largest producer and supplier of bovine embryos in North America. The combined tools and expertise of Intrexon and Trans Ova should enable the companies to accelerate efficiency in related food and protein production.  Established an Exclusive Channel Collaboration with Sanofi Chimie, a wholly owned subsidiary of Sanofi, to develop an e...